Table 1

Characteristics of 43 patients with OI (for patients with two OIs, characteristics at the first OI are presented)

Age (years), mean±SD (median)50.7±16.6 (51.0)
Sex (female)25 (58.1)
Underlying inflammatory disease
 Rheumatoid arthritis26 (60.5)
 Spondyloarthritis (ankylosing spondylitis or psoriatic arthritis)3 (7.0)
 Crohn's disease or ulcerative colitis8 (18.6)
 Psoriasis1 (2.3)
 Polyarteritis nodosa1 (2.3)
 Idiopathic juvenile arthritis1 (2.3)
 Sarcoidosis1 (2.3)
 Mesenteric fibrosis1 (2.3)
 Pyoderma gangrenosum1 (2.3)
Duration of the underlying inflammatory disease (years), mean±SD (median)11.3±8.1 (9.5)
Anti-TNF treatment
 One anti-TNF agent received34 (79.1)
 Two anti-TNF agents received successively6 (14.0)
 Three anti-TNF agents received successively3 (7.0)
Last anti-TNF agent received
 Adalimumab10 (23.3)
 Etanercept4 (9.3)
 Infliximab29 (67.4)
Ever used adalimumab12 (27.9)
Ever used etanercept, mean±SD (median)9 (20.9)
Ever used infliximab, mean±SD (median)34 (79.1)
Months since first anti-TNF treatment start*, mean±SD (median)18.2±14.9 (16.2)
Months since last anti-TNF treatment start*, mean±SD (median)13.3±13.1 (8.7)
Immunosuppressive DMARDs during the previous year37 (86.0)
Steroids during the previous year34 (79.1)
Oral steroids >10 mg/day during the previous year19 (44.2)
Steroids >10 mg/day or boluses during the previous year22 (51.2)
  • Data are number (%) unless stated otherwise.

  • * Time from onset of first/last anti-TNF treatment to first symptoms of OI.

  • Immunosuppressive disease-modifying anti-rheumatic drugs: at least one of mycophenolate mofetil, chlorambucil, ciclosporin, cyclophosphamide, mercaptopurine, methotrexate, leflunomide, azathioprine, abatacept, anakinra, certolizumab, rituximab.

  • DMARD, disease-modifying antirheumatic drug; OI, opportunistic infection; TNF, tumour necrosis factor.